Want to see GOSS full AI Analyst Report?

Gossamer Bio (GOSS) Price & Analysis

1,460 Followers

GOSS Stock Chart & Stats

$0.20

>-$0.01(-4.56%)

At close: Jul 24 4:00 PM EDT

$0.20

>-$0.01(-4.56%)

Day’s Range― - ―

52-Week Range$8.29 - $309.52

Previous CloseN/A

Volume10.93M

Average Volume (3M)303.67K

Market Cap

$58.54M

Enterprise Value$37.16M

Total Cash (Recent Filing)$57.03M

Total Debt (Recent Filing)$39.10M

Price to Earnings (P/E)―

Beta1.56

Next Earnings

Nov 05, 2026

EPS Estimate

-3.79

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-45.32

Shares Outstanding6,110,584

10 Day Avg. Volume252,705

30 Day Avg. Volume303,665

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)-5.77

Price to Sales (P/S)14.62

P/FCF Ratio-4.13

Enterprise Value/Market Cap0.63

Enterprise Value/Revenue0.70

Enterprise Value/Gross Profit0.70

Enterprise Value/Ebitda-0.18

Forecast

1Y Price Target

$86.48

Price Target Upside43140.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

EPS Forecast (FY)-15.59

Revenue Forecast (FY)$35.86M

Bulls Say, Bears Say

Bulls Say

Regulatory ProgressThe NDA submission moves seralutinib into formal FDA review after Phase 3 and Phase 2 evidence, creating a defined regulatory pathway. Acceptance and later approval could establish a commercial product and materially change Gossamer’s revenue profile and strategic position.

Control Of SeralutinibRegaining worldwide control gives Gossamer authority over development, manufacturing, pricing, and commercialization of its lead asset. Although royalties and milestones remain payable, greater control could allow the company to capture more of the product’s future economics if regulatory and commercial milestones are achieved.

Regulatory Funding RunwayCommitted and potential financing tied to seralutinib milestones is intended to support operations into 2028 and fund late-stage development. This extends the company’s ability to pursue regulatory and commercialization milestones, reducing immediate execution pressure while preserving access to capital.

Bears Say

Deep UnprofitabilityLosses remain extremely large relative to the company’s modest revenue base, despite an improvement in net loss from 2025. Such negative operating economics show that Gossamer has not yet demonstrated sustainable profitability and will require successful development or commercialization to improve earnings power.

Persistent Cash BurnHeavy cash outflows indicate that ongoing operations and development require substantial external funding. Although burn improved directionally from 2025, the remaining deficit increases dependence on financing and leaves less flexibility if regulatory progress, capital access, or commercialization timing does not meet expectations.

Negative Equity And Asset BaseNegative equity and a substantially smaller asset base indicate limited balance-sheet resilience while the company continues funding losses. This weakens financial flexibility, reduces the cushion available to absorb setbacks, and increases the importance of future financing and successful execution around seralutinib.

Gossamer Bio News

Chardan biotech/pharma analysts hold analyst/industry conference call

Biotech & Pharma Analysts discuss pulmonary arterial hypertension (PAH) and PAH associated with interstitial lung disease (PH-ILD) (relevant...

10d ago

IKT

GOSS

Adobe downgraded, VF Corp. upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

10d ago

Gossamer Bio initiated with a Buy at Chardan

Chardan analyst Andreas Argyrides initiated coverage of Gossamer Bio (GOSS) with a Buy rating and $160 price target...

10d ago

GOSS

Closing Bell Movers: Stitch Fix down 18% after results and guidance

U.N. General Assembly standoff pitting President Trump’s threat to annihilate Iran against a defiant tone from Iranian President...

29d ago

FUL

Gossamer Bio submits New Drug Application to FDA for seralutinib

Gossamer Bio (GOSS) announced that it submitted a New Drug Application to the U.S. Food and Drug Administration...

30d ago

GOSS

Gossamer Bio submits New Drug Application to FDA for seralutinib

Gossamer Bio (GOSS) announced that it submitted a New Drug Application to the U.S. Food and Drug Administration...

30d ago

GOSS

Gossamer Bio Regains Nasdaq Listing Bid Price Compliance

The latest update is out from Gossamer Bio ( ($GOSS) ). On September 25, 2026, Gossamer Bio, Inc....

25d ago

GOSS

Gossamer Bio Files First NDA for Seralutinib PAH Drug

Gossamer Bio ( ($GOSS) ) has shared an update. On September 23, 2026, Gossamer Bio, Inc. reported that...

30d ago

GOSS

Gossamer Bio target adjusted to $90 for split at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio adjusted the firm’s price target on Gossamer Bio (GOSS) to $90 from $2...

1M ago

GOSS

Gossamer Bio Defendants Move to Dismiss Securities Lawsuit Over PROSERA Trial Disclosures

Gossamer Bio, Inc. ($GOSS) and two of its executives have asked a federal court to dismiss a securities...

1M ago

GOSS

Gossamer Bio Adds Veteran Investor to Board of Directors

Gossamer Bio ( ($GOSS) ) has shared an update. On September 16, 2026, Gossamer Bio appointed veteran investor...

1M ago

GOSS

Gossamer Bio Executes Reverse Stock Split and Share Reduction

The latest announcement is out from Gossamer Bio ( ($GOSS) ). On September 10, 2026, Gossamer Bio implemented...

1M ago

GOSS

Gossamer Bio announces effectiveness of 1-for-80 reverse stock split

Gossamer Bio (GOSS) announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate...

1M ago

GOSS

Gossamer Bio trading halted, news pending

19:50 EDT Gossamer Bio (GOSS) trading halted, news pending Published first on TheFly – the ultimate source for...

1M ago

GOSS

GOSS FAQ

What was Gossamer Bio Inc’s price range in the past 12 months?

Gossamer Bio Inc lowest stock price was $8.29 and its highest was $309.52 in the past 12 months.

What is Gossamer Bio Inc’s market cap?

Gossamer Bio Inc’s market cap is $58.54M.

When is Gossamer Bio Inc’s upcoming earnings report date?

Gossamer Bio Inc’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.

How were Gossamer Bio Inc’s earnings last quarter?

Gossamer Bio Inc released its earnings results on Aug 13, 2026. The company reported -$6.4 earnings per share for the quarter, beating the consensus estimate of -$9.874 by $3.474.

Is Gossamer Bio Inc overvalued?

According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gossamer Bio Inc pay dividends?

Gossamer Bio Inc does not currently pay dividends.

What is Gossamer Bio Inc’s EPS estimate?

Gossamer Bio Inc’s EPS estimate is -3.79.

How many shares outstanding does Gossamer Bio Inc have?

Gossamer Bio Inc has 6,110,584 shares outstanding.

What happened to Gossamer Bio Inc’s price movement after its last earnings report?

Gossamer Bio Inc reported an EPS of -$6.4 in its last earnings report, beating expectations of -$9.874. Following the earnings report the stock price went down -9.454%.

Which hedge fund is a major shareholder of Gossamer Bio Inc?

Currently, no hedge funds are holding shares in GOSS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Gossamer Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

108.75%

Trailing 12-Months

Asset Growth

-68.09%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio (GOSS) Earnings & Revenues

Historic Earnings Reports

GOSS Stock 12 Month Forecast

Average Price Target

$86.48

▲(43140.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","252":"$252","69.75":"$69.8","130.5":"$130.5","191.25":"$191.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":160,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$160.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86.48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$86.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,69.75,130.5,191.25,252],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.93,22.396923076923077,33.863846153846154,45.33076923076923,56.79769230769231,68.26461538461538,79.73153846153846,91.19846153846154,102.66538461538462,114.1323076923077,125.59923076923079,137.06615384615384,148.53307692307692,{"y":160,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.93,16.74153846153846,22.553076923076922,28.364615384615387,34.17615384615385,39.98769230769231,45.799230769230775,51.610769230769236,57.4223076923077,63.23384615384616,69.04538461538462,74.85692307692308,80.66846153846154,{"y":86.48,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.93,11.812307692307693,12.694615384615384,13.576923076923077,14.459230769230768,15.34153846153846,16.223846153846154,17.106153846153845,17.988461538461536,18.87076923076923,19.75307692307692,20.635384615384616,21.517692307692307,{"y":22.4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":199.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":248,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.288,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.584,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.848,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.415,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.559,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.392,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.93,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >